
ASCENTAGE PH.GRP SP.ADR/4
Share · US04390B1052 · AAPG · A40ZYR (XNMS)
26,36 EUR
10.06.2025 16:15
Current Prices from ASCENTAGE PH.GRP SP.ADR/4
Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
---|---|---|---|---|---|
![]() NASDAQ |
AAPG
|
USD
|
10.06.2025 16:15
|
30,13 USD
| 29,88 USD
+0,84 %
|
Rendimiento
Día | Semana | Mes | 3 meses | 6 meses | 1 año | 5 años |
---|---|---|---|---|---|---|
0,64 % | 8,56 % | 22,15 % | 44,61 % | 47,05 % | 50,34 % | 58,84 % |
Perfil de la empresa para ASCENTAGE PH.GRP SP.ADR/4 Acción
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Datos de la empresa
Nombre ASCENTAGE PH.GRP SP.ADR/4
Empresa Ascentage Pharma Group International
Símbolo AAPG
Sitio web
https://www.ascentage.cn
Mercado principal
Frankfurt

WKN A40ZYR
ISIN US04390B1052
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Dajun Yang M.D., Ph.D.
Capitalización de mercado 2 Mrd.
País China
Moneda EUR
Empleados 0,6 T
Dirección Suzhou Industrial Park, 215000 Suzhou
Fecha de OPV 2025-01-24
Kennungs-Wechsel
Datum | Von | Zu |
---|---|---|
27.01.2025 | AAPGV | AAPG |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | 36X0.F |
NASDAQ | AAPG |
Weitere Aktien
Investoren die ASCENTAGE PH.GRP SP.ADR/4 die halten, haben auch folgende Aktien im Depot:
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.